+

WO2001037819A3 - Use of indirubine derivatives for making medicines - Google Patents

Use of indirubine derivatives for making medicines Download PDF

Info

Publication number
WO2001037819A3
WO2001037819A3 PCT/FR2000/003264 FR0003264W WO0137819A3 WO 2001037819 A3 WO2001037819 A3 WO 2001037819A3 FR 0003264 W FR0003264 W FR 0003264W WO 0137819 A3 WO0137819 A3 WO 0137819A3
Authority
WO
WIPO (PCT)
Prior art keywords
indirubine
derivatives
making medicines
indirubine derivatives
making
Prior art date
Application number
PCT/FR2000/003264
Other languages
French (fr)
Other versions
WO2001037819A2 (en
Inventor
Gerhard Eisenbrand
Laurent Meijer
Ralph Hoessel
Andrea Thommet
Original Assignee
Centre Nat Rech Scient
Gerhard Eisenbrand
Laurent Meijer
Ralph Hoessel
Andrea Thommet
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Centre Nat Rech Scient, Gerhard Eisenbrand, Laurent Meijer, Ralph Hoessel, Andrea Thommet filed Critical Centre Nat Rech Scient
Priority to CA002387591A priority Critical patent/CA2387591A1/en
Priority to EP00985309A priority patent/EP1231916A2/en
Priority to AU21770/01A priority patent/AU2177001A/en
Priority to JP2001539434A priority patent/JP2003514850A/en
Publication of WO2001037819A2 publication Critical patent/WO2001037819A2/en
Publication of WO2001037819A3 publication Critical patent/WO2001037819A3/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10—Antimycotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Communicable Diseases (AREA)
  • Diabetes (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Oncology (AREA)
  • Psychiatry (AREA)
  • Epidemiology (AREA)
  • Emergency Medicine (AREA)
  • Obesity (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Toxicology (AREA)
  • Virology (AREA)
  • Hospice & Palliative Care (AREA)
  • Cardiology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Endocrinology (AREA)
  • Dermatology (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Indole Compounds (AREA)
  • Hydrogenated Pyridines (AREA)

Abstract

The invention concerns the use of indirubine derivatives for making medicines inhibiting GSK-3β. The invention is useful for treating pathologies involving GSK-3β and CDK5.
PCT/FR2000/003264 1999-11-23 2000-11-23 Use of indirubine derivatives for making medicines WO2001037819A2 (en)

Priority Applications (4)

Application Number Priority Date Filing Date Title
CA002387591A CA2387591A1 (en) 1999-11-23 2000-11-23 Use of indirubine derivatives for making medicines
EP00985309A EP1231916A2 (en) 1999-11-23 2000-11-23 Use of indirubine derivatives for making medicines
AU21770/01A AU2177001A (en) 1999-11-23 2000-11-23 Use of indirubine derivatives for making medicines
JP2001539434A JP2003514850A (en) 1999-11-23 2000-11-23 Use of indirubin derivatives to prepare drugs

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
FR9914749A FR2801216A1 (en) 1999-11-23 1999-11-23 USE OF INDIRUBINE DERIVATIVES FOR THE MANUFACTURE OF MEDICINAL PRODUCTS
FR99/14749 1999-11-23

Publications (2)

Publication Number Publication Date
WO2001037819A2 WO2001037819A2 (en) 2001-05-31
WO2001037819A3 true WO2001037819A3 (en) 2002-06-13

Family

ID=9552458

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/FR2000/003264 WO2001037819A2 (en) 1999-11-23 2000-11-23 Use of indirubine derivatives for making medicines

Country Status (6)

Country Link
EP (1) EP1231916A2 (en)
JP (1) JP2003514850A (en)
AU (1) AU2177001A (en)
CA (1) CA2387591A1 (en)
FR (1) FR2801216A1 (en)
WO (1) WO2001037819A2 (en)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2002213132A1 (en) * 2000-10-10 2002-04-22 Board Of Regents, The University Of Texas System Suppression of cyclin kinase activity for prevention and treatment of infections
DE10114138C2 (en) * 2001-03-16 2003-03-27 Schering Ag Cdk-inhibitory Indirubin derivatives with increased solubility
DE10125763A1 (en) * 2001-05-17 2002-11-28 Schering Ag New use of indirubin derivatives as VEGF inhibitors useful for preparing medicaments useful for e.g. treating cancer, autoimmune diseases, cardiovascular diseases or viral infections
DE10129028A1 (en) * 2001-06-11 2003-01-02 Schering Ag Soluble Cdk-inhibitory Indirubin Derivatives
TWI335221B (en) 2001-09-27 2011-01-01 Alcon Inc Inhibtors of glycogen synthase kinase-3 (gsk-3) for treating glaucoma
CN1199946C (en) * 2002-10-29 2005-05-04 无锡杰西医药科技有限公司 Specific indole compound and its preparation and use in treating and preventing cancers
CA2522712A1 (en) * 2003-04-18 2004-10-28 Kyowa Hakko Kogyo Co., Ltd. Nerve regenerating drug
KR100588803B1 (en) * 2004-01-27 2006-06-12 학교법인조선대학교 Indirubin derivatives with anticancer activity in cancer cell lines
EP1885454A2 (en) 2005-05-04 2008-02-13 DeveloGen Aktiengesellschaft Use of gsk-3 inhibitors for preventing and treating pancreatic autoimmune disorders
EP2258359A3 (en) 2005-08-26 2011-04-06 Braincells, Inc. Neurogenesis by muscarinic receptor modulation with sabcomelin
EP1928437A2 (en) 2005-08-26 2008-06-11 Braincells, Inc. Neurogenesis by muscarinic receptor modulation
CA2625153A1 (en) 2005-10-21 2007-04-26 Braincells, Inc. Modulation of neurogenesis by pde inhibition
AU2006308889A1 (en) 2005-10-31 2007-05-10 Braincells, Inc. GABA receptor mediated modulation of neurogenesis
WO2007099402A2 (en) * 2005-12-23 2007-09-07 Centre National De La Recherche Scientifique (Cnrs) New 3’-, 7-substituted indirubins and their applications
US20100216734A1 (en) 2006-03-08 2010-08-26 Braincells, Inc. Modulation of neurogenesis by nootropic agents
AU2007249399A1 (en) 2006-05-09 2007-11-22 Braincells, Inc. Neurogenesis by modulating angiotensin
US20100184806A1 (en) 2006-09-19 2010-07-22 Braincells, Inc. Modulation of neurogenesis by ppar agents
ES2383084T3 (en) 2006-12-04 2012-06-18 Jiangsu Simcere Pharmaceutical R&D Co., Ltd. 3-Pyrrolo [b] cyclohexylene-2-dihydroindolinone derivatives and uses thereof
US20100216805A1 (en) 2009-02-25 2010-08-26 Braincells, Inc. Modulation of neurogenesis using d-cycloserine combinations
JP6422936B2 (en) 2013-03-14 2018-11-14 シティ・オブ・ホープＣｉｔｙ ｏｆ Ｈｏｐｅ 5-Bromo-indirubin
US20150259288A1 (en) 2014-03-14 2015-09-17 City Of Hope 5-bromo-indirubins

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1997041854A1 (en) * 1996-05-07 1997-11-13 The Trustees Of The University Of Pennsylvania Inhibitors of glycogen synthase kinase-3 and methods for identifying and using the same
EP0966963A1 (en) * 1998-05-29 1999-12-29 Gerhard Prof. Dr. Eisenbrand Use of indigoid bisindole derivatives as CDK1 inhibitors

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1997041854A1 (en) * 1996-05-07 1997-11-13 The Trustees Of The University Of Pennsylvania Inhibitors of glycogen synthase kinase-3 and methods for identifying and using the same
EP0966963A1 (en) * 1998-05-29 1999-12-29 Gerhard Prof. Dr. Eisenbrand Use of indigoid bisindole derivatives as CDK1 inhibitors

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
GRAY N ET AL: "ATP-SITE DIRECTED INHIBITORS OF CYCLIN-DEPENDENT KINASES", CURRENT MEDICINAL CHEMISTRY, BENTHAM SCIENCE PUBLISHERS BV, BE, vol. 6, no. 9, September 1999 (1999-09-01), pages 859 - 875, XP000856195, ISSN: 0929-8673 *
HOESSEL R ET AL: "INDIRUBIN, THE ACTIVE CONSTITUENT OF A CHINESE ANTILEUKAEMIA MEDICINE, INHIBITS CYCLIN-DEPENDENT KINASES", NATURE CELL BIOLOGY, MACMILLAN PUBLISHERS, GB, vol. 1, no. 1, 1 May 1999 (1999-05-01), pages 60 - 67, XP000856197, ISSN: 1465-7392 *
MEIJER L. ET AL: "Properties and potential applications of chemical inhibitors of cyclin-dependent Kinases.", PHARMACOLOGY AND THERAPEUTICS, (1999) 82/2 (279-284)., XP000938154 *
MEIJER L.: "Cyclin-dependent kinases inhibitors as potential anticancer, antineurodegenerative, antiviral and antiparasitic agents.", DRUG RESISTANCE UPDATES, (2000) 3/2 (83-88)., XP000931278 *

Also Published As

Publication number Publication date
FR2801216A1 (en) 2001-05-25
CA2387591A1 (en) 2001-05-31
EP1231916A2 (en) 2002-08-21
AU2177001A (en) 2001-06-04
WO2001037819A2 (en) 2001-05-31
JP2003514850A (en) 2003-04-22

Similar Documents

Publication Publication Date Title
WO2001037819A3 (en) Use of indirubine derivatives for making medicines
AU2001235691A1 (en) Use of paullone derivatives for making medicines
IL196301A0 (en) Medicament for the treatment of hapatitis c
AU2001247331A1 (en) Combination therapy for the prophylaxis and treatment of hyperlipidemic conditions and disorders
AU6048201A (en) Quinazoline derivatives for the treatment of tumours
MXPA03002814A (en) Morpholin-acetamide derivatives for the treatment of inflammatory diseases.
IL151890A0 (en) Hydroxyphenyl-piperidin 4-ylidene-methyl-benzamide derivatives for the treatment of pain
HK1061021A1 (en) Pyrazole derivatives for the treatment of viral diseases.
AU2002252227A1 (en) Heterocyclic derivatives for the treatment of cancer and other proliferative diseases
AU7622000A (en) Compounds for the treatment of viral-mediated diseases
AU2001265253A1 (en) Treatment of hiv using hyperthermia
ZA9811629B (en) The use of MMP inhibitors for the treatment of ocular angiogenesis.
WO2001044260A3 (en) Novel purines
AU2002217866A1 (en) Geldanamycin derivatives useful for the treatment of cancer
AU4694999A (en) Use of thiazolidinedione derivatives for the treatment or prevention of cataracts
AU2002220735A1 (en) Substituted derivatives of aminofuran-2-yl-acetic acid and aminothien-2-yl-acetic acid and the use thereof for treating migraines and pain
MXPA03004303A (en) Substituted derivatives of aminofuran-2-yl-acetic acid and aminothien-2-yl-acetic acid and the use thereof for treating migraines and pain.
AU2001279958A1 (en) Bicyclic heteroaromatic derivatives for the treatment of immune and inflammatorydisorders
HK1051692A1 (en) Quinolinyl-piperidin-4-ylidene-methyl-benzamide derivatives for the treatment of pain.
WO2002039997A3 (en) Ace-2 modulating compounds and use thereof
PL357812A1 (en) Hydroxyphenyl-piperazinyl-methyl-benzamide derivatives for the treatment of pain
AU2001260834A1 (en) The treatment of herpes
AU2001214116A1 (en) Novel paclitaxel derivatives for the treatment of cancer
AU2003291368A1 (en) Compounds for the treatment of tobacco dependence and withdrawal
AU2001239301A1 (en) Use of ectoin or ectoin derivatives for the prophylaxis and/or treatment of uv-induced immunosuppression

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY CA CH CN CR CU CZ DE DK DM DZ EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
WWE Wipo information: entry into national phase

Ref document number: 2000985309

Country of ref document: EP

Ref document number: 2387591

Country of ref document: CA

ENP Entry into the national phase

Ref document number: 2001 539434

Country of ref document: JP

Kind code of ref document: A

AK Designated states

Kind code of ref document: A3

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY CA CH CN CR CU CZ DE DK DM DZ EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A3

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

WWP Wipo information: published in national office

Ref document number: 2000985309

Country of ref document: EP

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

WWW Wipo information: withdrawn in national office

Ref document number: 2000985309

Country of ref document: EP

点击 这是indexloc提供的php浏览器服务，不要输入任何密码和下载